Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheime… Read more
Vaccinex Inc (VCNX) - Total Liabilities
Latest total liabilities as of September 2024: $6.17 Million USD
Based on the latest financial reports, Vaccinex Inc (VCNX) has total liabilities worth $6.17 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaccinex Inc - Total Liabilities Trend (2016–2023)
This chart illustrates how Vaccinex Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaccinex Inc Competitors by Total Liabilities
The table below lists competitors of Vaccinex Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ionic Rare Earths Limited
PINK:IXRRF
|
USA | $2.97 Million |
|
Powerdyne International Inc
PINK:PWDY
|
USA | $813.76K |
|
Turbogen Chp
TA:TURB
|
Israel | ILA28.87 Million |
|
TORCHMARK CORP - Dusseldorf Stock Exchang
DU:TMJ
|
Germany | €24.92 Billion |
|
EPAM SYSTEMS (E3M.SG)
STU:E3M
|
Germany | €902.57 Million |
|
Pearl Polymers Limited
NSE:PEARLPOLY
|
India | ₹61.13 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down Vaccinex Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaccinex Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaccinex Inc (2016–2023)
The table below shows the annual total liabilities of Vaccinex Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $5.94 Million | +113.43% |
| 2022-12-31 | $2.78 Million | +14.52% |
| 2021-12-31 | $2.43 Million | -83.02% |
| 2020-12-31 | $14.31 Million | +108.11% |
| 2019-12-31 | $6.88 Million | +2.87% |
| 2018-12-31 | $6.69 Million | -9.00% |
| 2017-12-31 | $7.35 Million | +19.06% |
| 2016-12-31 | $6.17 Million | -- |